Alerts will be sent to your verified email
Verify EmailLINCOLN
|
Lincoln Pharma
|
Sakar Healthcare
|
Venus Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
8.98 % | n/a | n/a |
|
R&D as a % of Total Sales
|
1.88 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
15.1 % | 8.14 % | 8.87 % |
|
5yr average Equity Multiplier
|
1.26 | 1.76 | 1.32 |
|
5yr Average Asset Turnover Ratio
|
0.82 | 0.45 | 0.96 |
|
5yr Avg Net Profit Margin
|
14.59 % | 10.03 % | 6.91 % |
|
Price to Book
|
1.34 | 3.12 | 1.78 |
|
P/E
|
12.03 | 48.46 | 15.06 |
|
5yr Avg Cash Conversion Cycle
|
-6.41 Days | 18.72 Days | 46.96 Days |
|
Inventory Days
|
43.91 Days | 51.79 Days | 75.64 Days |
|
Days Receivable
|
91.75 Days | 53.06 Days | 54.28 Days |
|
Days Payable
|
128.38 Days | 115.64 Days | 58.86 Days |
|
5yr Average Interest Coverage Ratio
|
63.13 | 4.85 | 396.11 |
|
5yr Avg ROCE
|
19.81 % | 8.92 % | 8.42 % |
|
5yr Avg Operating Profit Margin
|
18.35 % | 24.94 % | 10.14 % |
|
5 yr average Debt to Equity
|
0.0 | 0.49 | 0.08 |
|
5yr CAGR Net Profit
|
5.76 % | 10.38 % | -6.01 % |
|
5yr Average Return on Assets
|
11.92 % | 4.54 % | 6.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
49.78 % | 52.86 % | 41.76 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
5.7 % | -9.24 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Lincoln Pharma
|
Sakar Healthcare
|
Venus Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|